GLP-1 RECEPTOR AGONISTS

TRANSFORMING THE FUTURE OF DIABETES & WEIGHT MANAGEMENT

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are rewriting the rules of chronic disease treatment. Originally developed to manage Type 2 Diabetes (T2D), these medications are now at the forefront of a healthcare transformation—delivering powerful benefits for both blood sugar control and weight loss.

By mimicking natural gut hormones, GLP-1s help the body:

• Release more insulin when needed
• Reduce appetite
• Slow digestion
• Improve overall metabolic health

What began as a tool for diabetes has quickly evolved into one of the most exciting categories in modern medicine.

From Diabetes to Weight Loss—and So Much More

The momentum is unstoppable. Clinical breakthroughs have expanded GLP-1 use into weight management, and the results are remarkable. These medications are now helping millions achieve better health outcomes – and demand is skyrocketing.

Why does this matter? Because the numbers don’t lie:

• As of 2025, over 38 million Americans are living with diabetes.
• Childhood diabetes is rising rapidly.
• And by 2030, nearly half of U.S. adults are projected to be obese.

These trends signal a health crisis – but they also highlight a massive opportunity for innovation. GLP-1s are leading the charge.

Meet the All-Stars: GLP-1 RAs for Diabetes

* Tirzepatide also activates GIP receptors, giving it a unique advantage in both weight and glycemic management.

GLP-1s for Weight Loss: Breaking Barriers

These therapies have opened the door to a more hopeful future for millions battling obesity. They’re not quick fixes – they’re powerful tools for long-term change.

GLP-1s: A Multitasking Marvel

GLP-1s are proving to be more than just diabetes and weight medications. They’re showing promise in:

• Heart Disease: Proven reduction in cardiovascular risk (semaglutide, liraglutide)
• Fatty Liver Disease (NAFLD/NASH): Ongoing studies show strong potential
• PCOS: Supporting weight loss and insulin sensitivity in women with PCOS
• Neurological Disorders: Early signs of neuroprotection in Alzheimer’s and Parkinson’s

GLP-1s could soon play a role in nearly every corner of chronic disease care.

Side Effects: What to Expect

Yes, GLP-1s can cause side effects – but most are mild, manageable, and temporary.

Tips for smoother experience:

• Start low, go slow
• Stay hydrated
• Contact your doctor if symptoms persist

The Market is Booming—And It’s Just Getting Started

The GLP-1 revolution is in full swing—and the market is heating up!

Market Momentum

• Expected to hit $90 billion globally by 2030
• Wegovy and Zepbound are flying off the shelves
• Pharmaceutical leaders are racing to develop next-gen versions

Innovation is Exploding

• CagriSema: A combo of GLP-1 and amylin for next-level weight loss
• Triple Agonists: Target GLP-1, GIP, and glucagon – hello, metabolic magic!
• Monthly Dosing & New Oral Forms: Designed for real-world convenience

Coverage and Affordability

• Access is still a hurdle, especially for weight loss-only indications
• Biosimilars are on the horizon, which could improve affordability
• Direct-to-consumer ads are raising awareness and driving demand

The Bottom Line

GLP-1 receptor agonists aren’t just a trend – they’re a transformation. These therapies are rewriting the rules of diabetes and obesity treatment, and their potential is growing by the day.

What’s next?

• More innovation
• Better access
• Expanded uses in new disease states

The future of chronic disease management looks brighter – and GLP-1s are lighting the way.

References

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2025. Atlanta, GA: CDC, US Dept of Health and Human Services; 2025.
2. American Diabetes Association. Statistics About Diabetes. Available at: https://diabetes.org/about-diabetes/statistics.
3. Healy M. By 2030, nearly half of all U.S. adults will be obese, experts predict. National Library of Medicine.
4. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.
5. Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1 Receptor Agonists. Lancet Diabetes Endocrinol. 2018;6(11):891-899.
6. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5-21.
7. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: A review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:2042018821997320.
8. U.S. Food and Drug Administration. Ozempic (semaglutide) injection, for subcutaneous use – Prescribing Information. Revised 2023. Available at: https://www.accessdata.fda.gov.
9. U.S. Food and Drug Administration. Wegovy (semaglutide) injection, for subcutaneous use – Prescribing Information. Revised 2023. Available at: https://www.accessdata.fda.gov.
10. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.

###

ABOUT CERPASSRX

CerpassRx, a leading full-service PBM, is renowned for its tailored solutions addressing diverse client needs. Its distinctive approach encompasses prescription optimization programs, flexible formulary designs, personalized member services, and efficient mail delivery and specialty pharmacy programs. Integrating top-tier pharmacy tools and expertise with premier PBM services, CerpassRx exemplifies excellence. Central to its core values are collaboration, accountability, passion, and empowerment. By prioritizing these principles, CerpassRx empowers clients, fostering an alliance built on trust and mutual success. The company’s mission is clear: to redefine standards and push boundaries, ultimately driving positive change and heightened efficiency in pharmacy benefit management.